130 related articles for article (PubMed ID: 24582801)
1. The influence of comorbidity on mortality in ovarian cancer patients.
Stålberg K; Svensson T; Lönn S; Kieler H
Gynecol Oncol; 2014 May; 133(2):298-303. PubMed ID: 24582801
[TBL] [Abstract][Full Text] [Related]
2. Patterns and progress in ovarian cancer over 14 years.
Chan JK; Cheung MK; Husain A; Teng NN; West D; Whittemore AS; Berek JS; Osann K
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):521-8. PubMed ID: 16946210
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012.
Trétarre B; Molinié F; Woronoff AS; Bossard N; Bessaoud F; Marrer E; Grosclaude P; Guizard AV; Delafosse P; Bara S; Velten M; Lapôtre-Ledoux B; Ligier K; Léone N; Arveux P; Uhry Z
Gynecol Oncol; 2015 Nov; 139(2):324-9. PubMed ID: 26383829
[TBL] [Abstract][Full Text] [Related]
4. Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
van der Hel OL; Timmermans M; van Altena AM; Kruitwagen RFPM; Slangen BFM; Sonke GS; van de Vijver KK; van der Aa MA
Eur J Cancer; 2019 Sep; 118():97-104. PubMed ID: 31326731
[TBL] [Abstract][Full Text] [Related]
5. The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study.
O'Malley CD; Shema SJ; Cress RD; Bauer K; Kahn AR; Schymura MJ; Wike JM; Stewart SL
J Womens Health (Larchmt); 2012 Sep; 21(9):887-94. PubMed ID: 22816528
[TBL] [Abstract][Full Text] [Related]
6. Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
Sköld C; Koliadi A; Enblad G; Stålberg K; Glimelius I
Int J Cancer; 2022 Mar; 150(5):773-781. PubMed ID: 34648676
[TBL] [Abstract][Full Text] [Related]
7. Intrauterine factors and risk of nonepithelial ovarian cancers.
Sieh W; Sundquist K; Sundquist J; Winkleby MA; Crump C
Gynecol Oncol; 2014 May; 133(2):293-7. PubMed ID: 24530563
[TBL] [Abstract][Full Text] [Related]
8. Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study.
Noer MC; Leandersson P; Paulsen T; Rosthøj S; Antonsen SL; Borgfeldt C; Høgdall C
Acta Oncol; 2018 Aug; 57(8):1100-1108. PubMed ID: 29451070
[TBL] [Abstract][Full Text] [Related]
9. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
[TBL] [Abstract][Full Text] [Related]
10. Impact of cardiovascular comorbidity on ovarian cancer mortality.
Shinn EH; Lenihan DJ; Urbauer DL; Basen-Engquist KM; Valentine A; Palmero L; Woods ML; Patel P; Nick AM; Shahzad MM; Stone RL; Golden A; Atkinson E; Lutgendorf SK; Sood AK
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2102-9. PubMed ID: 24045927
[TBL] [Abstract][Full Text] [Related]
11. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
Matz M; Coleman MP; Sant M; Chirlaque MD; Visser O; Gore M; Allemani C;
Gynecol Oncol; 2017 Feb; 144(2):405-413. PubMed ID: 27931752
[TBL] [Abstract][Full Text] [Related]
12. Malignant ovarian tumours in childhood in Britain, 1962-78.
La Vecchia C; Morris HB; Draper GJ
Br J Cancer; 1983 Sep; 48(3):363-74. PubMed ID: 6311234
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer during pregnancy.
Gezginç K; Karataylı R; Yazıcı F; Acar A; Celik C; Capar M
Int J Gynaecol Obstet; 2011 Nov; 115(2):140-3. PubMed ID: 21872237
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prevalent and incident ovarian cancer co-morbidity.
Stålberg K; Svensson T; Granath F; Kieler H; Tholander B; Lönn S
Br J Cancer; 2012 May; 106(11):1860-5. PubMed ID: 22549177
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
16. Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.
Shai A; Rennert HS; Rennert G; Sagi S; Leviov M; Lavie O
Gynecol Oncol; 2014 May; 133(2):304-8. PubMed ID: 24631448
[TBL] [Abstract][Full Text] [Related]
17. Survival in ovarian cancer patients by histology and family history.
Ji J; Försti A; Sundquist J; Lenner P; Hemminki K
Acta Oncol; 2008; 47(6):1133-9. PubMed ID: 18607880
[TBL] [Abstract][Full Text] [Related]
18. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
19. Statin use and mortality among ovarian cancer patients: A population-based cohort study.
Verdoodt F; Kjaer Hansen M; Kjaer SK; Pottegård A; Friis S; Dehlendorff C
Int J Cancer; 2017 Jul; 141(2):279-286. PubMed ID: 28411390
[TBL] [Abstract][Full Text] [Related]
20. Socioeconomic status and epithelial ovarian cancer survival in Sweden.
Weiderpass E; Oh JK; Algeri S; Bellocco R
Cancer Causes Control; 2014 Aug; 25(8):1063-73. PubMed ID: 24906473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
